Showing results (451-460 of 1,188) with videos related to
Sort By:
Pageof 119
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2013
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trialsMusa Yilmaz, Hagop Kantarjian, Elias Jabbour, et al.Leukemia Research|March 13, 2016
Down-regulation of EZH2 expression in myelodysplastic syndromesMonica Cabrero, Yue Wei, Hui Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndromeHagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, et al.Antimicrobial Agents and Chemotherapy|December 24, 2008
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testingMaiken Cavling Arendrup, Guillermo Garcia-Effron, Walter Buzina, et al.Cancer|May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disordersJorge Cortes, Francis Giles, Susan O'Brien, et al.Cancer|April 25, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.BMC Hematology|May 6, 2016
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopeniaGuillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, et al.Alzheimer'S Research & Therapy|August 19, 2019
Souvenaid in the management of mild cognitive impairment: an expert consensus opinionJeffrey Cummings, Peter Passmore, Bernadette McGuinness, et al.American Journal of Hematology|June 4, 2014
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndromeGuillermo Garcia-Manero, Gary Gartenberg, David P Steensma, et al.Clinical Lymphoma, Myeloma & Leukemia|June 12, 2023
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up ResultsGeorgina Gener-Ricos, Fadi G Haddad, Koji Sasaki, et al.Pageof 119